Evaluation of microRNA-10b prognostic significance in a prospective cohort of breast cancer patients

Molecular Cancer

Volumn 13, Issue 1, 2014, Pages

  Parrella, Paola ^a   Barbano, Raffaela ^a   Pasculli, Barbara ^b   Fontana, Andrea ^a   Copetti, Massimiliano ^a   Valori, Vanna M ^a   Poeta, Maria L ^a   Perrone, Giuseppe ^c   Righi, Daniela ^c   Castelvetere, Marina ^a   Coco, Michelina ^a   Balsamo, Teresa ^a   Morritti, Maria ^a   Pellegrini, Fabio ^b,d   Onetti Muda, Andrea ^c   Maiello, Evaristo ^a   Murgo, Roberto ^a   Fazio, Vito M ^a,e  

^a CASA SOLLIEVO DELLA SOFFERENZA HOSPITAL   (Italy)

^b UNIVERSITY OF BARI   (Italy)

^c UNIVERSITY CAMPUS BIO MEDICO   (Italy)

^d MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^e Laboratory of Molecular Medicine and Biotechnology   (Italy)

Author keywords

Breast cancer; Metastasis; microRNA; RT qPCR

Indexed keywords

MICRORNA 10B; HOMEODOMAIN PROTEIN; HOXD10 PROTEIN, HUMAN; MICRORNA; MIRN10 MICRORNA, HUMAN; TRANSCRIPTION FACTOR; TUMOR MARKER;

ADULT; ARTICLE; BREAST CANCER; CANCER GROWTH; CANCER PATIENT; CANCER PROGNOSIS; CANCER SURVIVAL; COHORT ANALYSIS; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE FREE SURVIVAL; DISTANT METASTASIS; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; METASTASIS FREE SURVIVAL; NOTTINGHAM PROGNOSTIC INDICATOR; OVERALL SURVIVAL; PRACTICE GUIDELINE; PREDICTION; PROSPECTIVE STUDY; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR INVASION; AGED; BREAST NEOPLASMS; CANCER GRADING; CANCER STAGING; GENE EXPRESSION REGULATION; GENETICS; LYMPH NODE METASTASIS; METABOLISM; MIDDLE AGED; MORTALITY; PATHOLOGY; PREDICTIVE VALUE; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; SIGNAL TRANSDUCTION; SURVIVAL;

ADULT; AGED; BREAST NEOPLASMS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HOMEODOMAIN PROTEINS; HUMANS; LYMPHATIC METASTASIS; MICRORNAS; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM STAGING; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; SIGNAL TRANSDUCTION; SURVIVAL ANALYSIS; TRANSCRIPTION FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 84902254501     PISSN: None     EISSN: 14764598     Source Type: Journal    
DOI: 10.1186/1476-4598-13-142     Document Type: Article

References (36)

1. Jemal A, Bray F, Center M, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011, 61:69-90. 10.3322/caac.20107, 21296855.
2. Peto R, Davies C, Godwin J, Gray R, Pan HC, Clarke M, Cutter D, Darby S, McGale P, Taylor C, Wang YC, Bergh J, Di Leo A, Albain K, Swain S, Piccart M, Pritchard K, . Early Breast Cancer Trialists' Collaborative Group (EBCTCG) Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials. Lancet 2012, 379:432-444. 3273723, 22152853, Early Breast Cancer Trialists' Collaborative Group (EBCTCG).
3. Valastyan S, Weinberg RA. Tumor metastasis: molecular insight and evolving paradigms. Cell 2011, 147:275-292. 10.1016/j.cell.2011.09.024, 3261217, 22000009.
4. Iorio MV, Croce CM. Causes and consequences of microRNA dysregulation. Cancer J 2012, 18:215-222. 10.1097/PPO.0b013e318250c001, 3528102, 22647357.
5. Ma L, Teruya-Feldstein J, Weinberg RA. Tumour invasion and metastasis initiated by microRNA-10b in breast cancer. Nature 2007, 449:682-688. 10.1038/nature06174, 17898713.
6. Ma L, Reinhardt F, Pan E, Soutschek J, Bhat B, Marcusson EG, Teruya-Feldstein J, Bell GW, Weinberg RA. Therapeutic silencing of miR-10b inhibits metastasis in a mouse mammary tumor model. Nat Biotechnol 2010, 28:341-347. 10.1038/nbt.1618, 2852471, 20351690.
7. Fassan M, Baffa R, Palazzo JP, Lloyd J, Crosariol M, Liu CG, Volinia S, Alder H, Rugge M, Croce CM, Rosenberg A. MicroRNA expression profiling of male breast cancer. Breast Cancer Res 2009, 11:R58. 10.1186/bcr2348, 2750120, 19664288.
8. Jin H, Yu Y, Chrisler WB, Xiong Y, Hu D, Lei C. Delivery of MicroRNA-10b with polylysine nanoparticles for inhibition of breast cancer cell wound healing. Breast Cancer (Auckl) 2012, 6:9-19. 3256732, 22259248.
9. Negrini M, Calin GA. Breast cancer metastasis: a microRNA story. Breast Cancer Res 2008, 10:203.
10. Sun L, Yan W, Wang Y, Sun G, Luo H, Zhang J, Wang X, You Y, Yang Z, Liu N. MicroRNA-10b induces glioma cell invasion by modulating MMP-14 and uPAR expression via HOXD10. Brain Res 2011, 1389:9-18.
11. Zaravinos A, Radojicic J, Lambrou GI, Volanis D, Delakas D, Stathopoulos EN, Spandidos DA. Expression of miRNAs involved in angiogenesis, tumor cell proliferation, tumor suppressor inhibition, epithelial-mesenchymal transition and activation of metastasis in bladder cancer. J Urol 2012, 188:615-623. 10.1016/j.juro.2012.03.122, 22704449.
12. Liu Y, Zhao J, Zhang PY, Zhang Y, Sun SY, Yu SY, Xi QS. MicroRNA-10b targets E-cadherin and modulates breast cancer metastasis. Med Sci Monit 2012, 18:299-308.
13. Baffa R, Fassan M, Volinia S, Hara B, Liu CG, Palazzo JP, Gardiman M, Rugge M, Gomella LG, Croce CM, Rosenberg A. MicroRNA expression profiling of human metastatic cancers identifies cancer gene targets. J Pathol 2009, 219:214-221. 10.1002/path.2586, 19593777.
14. Li X, Zhang Y, Zhang Y, Ding J, Wu K, Fan D. Survival prediction of gastric cancer by a seven-microRNA signature. Gut 2010, 59:579-585. 10.1136/gut.2008.175497, 19951901.
15. Heinzelmann J, Henning B, Sanjmyatav J, Posorski N, Steiner T, Wunderlich H, Gajda MR, Junker K. Specific miRNA signatures are associated with metastasis and poor prognosis in clear cell renal cell carcinoma. World J Urol 2011, 29:367-373. 10.1007/s00345-010-0633-4, 21229250.
16. Vickers MM, Bar J, Gorn-Hondermann I, Yarom N, Daneshmand M, Hanson JE, Addison CL, Asmis TR, Jonker DJ, Maroun J, Lorimer IA, Goss GD, Dimitroulakos J. Stage-dependent differential expression of microRNAs in colorectal cancer: potential role as markers of metastatic disease. Clin Exp Metastasis 2012, 29:123-132. 10.1007/s10585-011-9435-3, 22120473.
17. Preis M, Gardner TB, Gordon SR, Pipas JM, Mackenzie TA, Klein EE, Longnecker DS, Gutmann EJ, Sempere LF, Korc M. MicroRNA-10b expression correlates with response to neoadjuvant therapy and survival in pancreatic ductal adenocarcinoma. Clin Cancer Res 2011, 17:5812-5821. 10.1158/1078-0432.CCR-11-0695, 3167031, 21652542.
18. Nishida N, Yamashita S, Mimori K, Sudo T, Tanaka F, Shibata K, Yamamoto H, Ishii H, Doki Y, Mori M. MicroRNA-10b is a prognostic indicator in colorectal cancer and confers resistance to the chemotherapeutic agent 5-fluorouracil in colorectal cancer cells. Ann Surg Oncol 2012, 19:3065-3071. 10.1245/s10434-012-2246-1, 22322955.
19. Chang KH, Miller N, Kheirelseid EA, Lemetre C, Ball GR, Smith MJ, Regan M, McAnena OJ, Kerin MJ. MicroRNA signature analysis in colorectal cancer: identification of expression profiles in stage II tumors associated with aggressive disease. Int J Colorectal Dis 2011, 26:1415-1422. 10.1007/s00384-011-1279-4, 21739196.
20. Zhao F, Hu GD, Wang XF, Zhang XH, Zhang YK, Yu ZS. Serum overexpression of microRNA-10b in patients with bone metastatic primary breast cancer. J Int Med Res 2012, 40:859-866. 10.1177/147323001204000304, 22906258.
21. Gee HE, Camps C, Buffa FM, Colella S, Sheldon H, Gleadle JM, Ragoussis J, Harris AL. MicroRNA-10b and breast cancer metastasis. Nature 2008, 455:E8-E9. author reply, 10.1038/nature07362, 18948893.
22. Iorio MV, Ferracin M, Liu CG, Veronese A, Spizzo R, Sabbioni S, Magri E, Pedriali M, Fabbri M, Campiglio M, Ménard S, Palazzo JP, Rosenberg A, Musiani P, Volinia S, Nenci I, Calin GA, Querzoli P, Negrini M, Croce CM. MicroRNA gene expression deregulation in human breast cancer. Cancer Res 2005, 65:7065-7070. 10.1158/0008-5472.CAN-05-1783, 16103053.
23. Radojicic JZA, Vrekoussis T, Kafousi M, Spandidos DA, Stathopoulos EN. MicroRNA expression analysis in triple-negative (ER, PR and Her2/neu) breast cancer. Cell Cycle 2011, 10:507-517. 10.4161/cc.10.3.14754, 21270527.
24. Polyak K, Kalluri R. The role of the microenvironment in mammary gland development and cancer. Cold Spring Harb Perspect Biol 2010, 2:a003244. 2964182, 20591988.
25. Chan M, Liaw CS, Ji SM, Tan HH, Wong CY, Thike AA, Tan PH, Ho GH, Lee AS. Identification of circulating MicroRNA signatures for breast cancer detection. Clin Cancer Res 2013, 19:4477-4487. 10.1158/1078-0432.CCR-12-3401, 23797906.
26. McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM. Statistics subcommittee of the NCI-EORTC working group on cancer diagnostics. Reporting recommendations for tumor marker prognostic studies. J Clin Oncol 2005, 23:9067-9072. 10.1200/JCO.2004.01.0454, 16172462.
27. Hammond ME1, Hayes DF, Dowsett M, Allred DC, Hagerty KL, Badve S, Fitzgibbons PL, Francis G, Goldstein NS, Hayes M, Hicks DG, Lester S, Love R, Mangu PB, McShane L, Miller K, Osborne CK, Paik S, Perlmutter J, Rhodes A, Sasano H, Schwartz JN, Sweep FC, Taube S, Torlakovic EE, Valenstein P, Viale G, Visscher D, Wheeler T, Williams RB, Wittliff JL, Wolff AC. American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol 2010, 28:2784-2795. 10.1200/JCO.2009.25.6529, 2881855, 20404251.
28. Wolff AC, Hammond ME, Schwartz JN, Hagerty KL, Allred DC, Cote RJ, Dowsett M, Fitzgibbons PL, Hanna WM, Langer A, McShane LM, Paik S, Pegram MD, Perez EA, Press MF, Rhodes A, Sturgeon C, Taube SE, Tubbs R, Vance GH, van de Vijver M, Wheeler TM, Hayes DF. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 2007, 25:118-145.
29. Lee AH, Ellis IO. The Nottingham prognostic index for invasive carcinoma of the breast. Pathol Oncol Res 2008, 14:113-115. 10.1007/s12253-008-9067-3, 18543079.
30. Chen C, Ridzon DA, Broomer AJ, Zhou Z, Lee DH, Nguyen JT, Barbisin M, Xu NL, Mahuvakar VR, Andersen MR, Lao KQ, Livak KJ, Guegler KJ. Real-time quantification of microRNAs by stem-loop RT-PCR. Nucleic Acids Res 2005, 33:e179. 10.1093/nar/gni178, 1292995, 16314309.
31. Barbano R, Copetti M, Perrone G, Pazienza V, Muscarella LA, Balsamo T, Storlazzi CT, Ripoli M, Rinaldi M, Valori VM, Latiano TP, Maiello E, Stanziale P, Carella M, Mangia A, Pellegrini F, Bisceglia M, Muda AO, Altomare V, Murgo R, Fazio VM, Parrella P. High RAD51 mRNA expression characterize estrogen receptor-positive/progesteron receptor-negative breast cancer and is associated with patient's outcome. Int J Cancer 2011, 129:536-545. 10.1002/ijc.25736, 21064098.
32. Schoenfeld D. Partial residuals for the proportional hazards regression model. Biometrika 1982, 69:239-241.
33. Pencina MJ, Agostino RB. Overall C as a measure of discrimination in survival analysis: model specific population value and confidence interval estimation. Stat Med 2004, 23:2109-2123. 10.1002/sim.1802, 15211606.
34. Pencina MJ, D'Agostino RB, Vasan RS. Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond. Stat Med 2008, 27:157-172. 10.1002/sim.2929, 17569110.
35. Pencina MJ, Agostino RB, Steyerberg EW. Extensions of net reclassification improvement calculations to measure usefulness of new biomarkers. Stat Med 2011, 30:11-21. 10.1002/sim.4085, 3341973, 21204120.
36. Saphner T, Tormey DC, Gray R. Annual hazard rates of recurrence for breast cancer after primary therapy. J Clin Oncol 1996, 14:2738-2746.